🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

123 results for “Sanofi” Clear

  1. Match placebo to test product, Balinatunfib

    Sanofi Pharma Bristol-Myers Squibb

    Crohn's disease

    phase 2 small molecule active

    1 trial

  2. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi Pharma Bristol-Myers Squibb

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  3. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  4. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi Pharma Bristol-Myers Squibb

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  5. Matched placebo for test product, Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  6. Matched placebo for test product, SAR444336

    Sanofi Pharma Bristol-Myers Squibb

    Digestive system diseases

    phase 2 small molecule active

    1 trial

  7. Matched, SAR444656

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  8. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 small molecule active

    1 trial

  9. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi Pharma Bristol-Myers Squibb

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  10. Not the same excipients as Test, Balinatunfib

    Sanofi Pharma Bristol-Myers Squibb

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  11. PEGENZILEUKIN, Isatuximab, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  12. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  13. PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579

    Sanofi Pharma Bristol-Myers Squibb

    Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia

    phase 2 small molecule active

    1 trial

  14. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  15. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  16. Rilzabrutinib, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 small molecule active

    1 trial

  17. SAR421869

    Sanofi Pharma Bristol-Myers Squibb

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  18. SAR422459

    Sanofi Pharma Bristol-Myers Squibb

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  19. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  20. SAR442970, NANOBODY® Placebo

    Sanofi Pharma Bristol-Myers Squibb

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  21. SAR443765 / LUNSEKIMIG

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  22. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  23. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  24. SAR444656, Matched Placebo

    Sanofi Pharma Bristol-Myers Squibb

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources